Introduction {#s1}
============

Graves\' disease (GD) is an autoimmune thyroid disorder characterized by hyperthyroidism. It is commonly seen in young and middle-aged people, affecting 0.5--1.0% of the general population [@pone.0086077-Weetman1]. In GD, circulating autoantibodies are produced, which target well-defined thyroidal antigens, such as thyroid peroxidase, thyroglobulin, and the thyroid-stimulating hormone receptor (TSHR) [@pone.0086077-Prabhakar1]. Stimulatory autoantibodies binding to TSHR on thyroid follicular cells induce over-synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3). The systematic effects of elevated T3/T4 manifests as a sped up metabolism and its correlated symptoms. In addition to hyperthyroidism, some patients with GD have clinical involvement of the eyes resulting in Graves\' Ophthalmopathy (GO) and the skin resulting in localized myxoedema [@pone.0086077-Heufelder1], [@pone.0086077-Brinster1].

The etiology of GD remains unknown; however, it is considered to be caused by an interplay between genetic and environmental factors [@pone.0086077-Hemminki1], [@pone.0086077-Tomer1]. In common with other autoimmune diseases, GD has a complex genetic basis, with numerous different genes each contributing in various degrees to the inherited susceptibility. Using both the candidate gene approach and whole genome linkage studies, some major susceptibility genes to GD have been identified, including human leukocyte antigen (HLA) on chromosome 6p21, *Cytotoxic T-Lymphocyte Antigen (CTLA) -4* on chromosome 2q33 and *lymphoid tyrosine phosphatase (LYP)* on chromosome 1p13 [@pone.0086077-Velaga1]--[@pone.0086077-JureckaLubieniecka1]. Besides these, it is believed that additional genes contribute to the genetic susceptibility to GD, as well as to its different phenotypes. Much interest has currently centered around the exploration of additional susceptibility genes to GD, which may help elucidate signaling pathways involved in the pathogenesis of GD, and help develop novel therapeutic strategies for the disease.

The interleukin-1 (IL-1) family is a group of related cytokines including two agonist proteins (IL-1A and IL-1B) and an antagonist protein (IL-1RA). The genes encoding for these molecules are located close to one another on chromosome 2q13-14, which are candidate genes for GD. There are several common polymorphisms that have been most frequently investigated. The *IL1B* gene has two single nucleotide polymorphisms (SNP) at position -511 in the promoter region (rs16944) and at position +3954 in the fifth exon (rs1143634), respectively [@pone.0086077-GarcaGonzlez1], [@pone.0086077-Stegger1]. In the *IL1RN* gene, the second intron contains a variable number of tandem repeats (VNTR) of 86 base pairs (rs2234663) [@pone.0086077-Jaiswal1]. Many genetic association studies have intensively investigated the association of these SNPs with GD risk; however, results from individual studies are not consistent [@pone.0086077-Blakemore1]--[@pone.0086077-Liu2]. Here we conducted a meta-analysis with pooled data from 11 genetic association studies to determine risk of GD associated with these three polymorphisms in the *IL-1* gene.

Materials and Methods {#s2}
=====================

Search strategy and selection of studies {#s2a}
----------------------------------------

We conducted a literature search for studies reporting on the association between *IL-1* gene polymorphisms and GD risk using the electronic database PubMed, Medline and Web of Science from January 1990 up to the end of July 2013. The search results were limited to publications in English. The search strategy used the key words "IL-1, Graves\' disease, thyroid disease, genetic, association, polymorphism, susceptibility". We also screened references of retrieved publications. Inclusion criteria were as follows: (a) case-control design; (b) sufficient data provided to reconstruct two by two tables or determine odds ratio and confidence intervals. Studies were excluded if one of the following existed: (a) no control; (b) no usable data reported.

Data extraction {#s2b}
---------------

Information on general study characteristics including first author, year of publication, country, ethnicity, sample size, and genotype distribution in cases and controls was collected from the published papers.

Statistical analyses {#s2c}
--------------------

Data were analyzed using Stata 11.0. We used raw data of genotype distribution, without adjustment for calculation of the study-specific estimates of odds ratio (OR) and 95% confidence interval (CI). Dominant, recessive and homozygote genetic models were employed to assess the relation of *IL-1* gene polymorphisms with GD risk. Z-test was conducted for assessing the significance of the pooled ORs, with p\<0.05 considered statistically significant. Cochran\' s Q test was used to test for heterogeneity, with significance level set at 0.10. The pooled estimation of the ORs of each publication was calculated with the fixed effects model (Mantel-Haenszel methods) in the absence of significant between-study heterogeneity [@pone.0086077-MANTEL1], while the random effects model (DerSimonian and Laird\' s method) was employed for results showing high heterogeneity [@pone.0086077-DerSimonian1]. We used Begg\' s test to evaluate publication bias.

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

[Figure 1](#pone-0086077-g001){ref-type="fig"} summarized the process of identifying eligible studies. After title and abstract evaluation we were left with 15 studies. Four studies were excluded after evaluating the remaining 15 articles in their entirety. Finally, 11 studies were included in the meta-analysis [@pone.0086077-Blakemore1]--[@pone.0086077-Mhlberg1], [@pone.0086077-Reichmann1]--[@pone.0086077-Liu1], [@pone.0086077-Liu2]. [Table 1](#pone-0086077-t001){ref-type="table"} summarizes the characteristics of the 11 studies according to the *IL-1* gene polymorphisms. Six studies investigated the *IL1B* (*-511*) polymorphism [@pone.0086077-Chen1], [@pone.0086077-KammounKrichen1]--[@pone.0086077-Liu1], [@pone.0086077-Liu2], six the *IL1B* (*+3954*) polymorphism [@pone.0086077-Reichmann1], [@pone.0086077-Chen1], [@pone.0086077-KammounKrichen1]--[@pone.0086077-Khalilzadeh1], [@pone.0086077-Liu2] and six studies the *IL1RN* (*VNTR*) polymorphism [@pone.0086077-Blakemore1]--[@pone.0086077-Mhlberg1], [@pone.0086077-Chen1]--[@pone.0086077-KammounKrichen1]. [Table 2](#pone-0086077-t002){ref-type="table"} summarizes genotype distribution of the *IL-1* gene polymorphisms.

![Flowchart of study selection process.](pone.0086077.g001){#pone-0086077-g001}

10.1371/journal.pone.0086077.t001

###### Characteristics of the studies evaluating *IL-1* gene polymorphisms and GD risk.

![](pone.0086077.t001){#pone-0086077-t001-1}

  First author                                              Year   Country or Area   Ethnicity    Patients (n)   Controls (n)                             Polymorphism
  -------------------------------------------------------- ------ ----------------- ------------ -------------- -------------- -------------------------------------------------------------------
  Blakemore et al. [@pone.0086077-Blakemore1]               1995         UK          Caucasians       100            261                                 *IL1RN (VNTR)*
  Cuddihy et al. [@pone.0086077-Cuddihy1]                   1996         USA         Caucasians       141            145                      *IL1A* (*+4845*) and *IL1RN* (*VNTR*)
  Mühlberg et al. [@pone.0086077-Mhlberg1]                  1998       Germany       Caucasians       144            174                                 *IL1RN (VNTR)*
  Reichmann et al. [@pone.0086077-Reichmann1]               2004       Germany       Caucasians        53            259                                *IL1B* (*+3954*)
  Chen et al. [@pone.0086077-Chen1]                         2005       Taiwan          Asians          95            163                 *IL1B (-511)* and *(+3954)* and *IL1RN (VNTR)*
  Nakkuntod et al. [@pone.0086077-Nakkuntod1]               2006      Thailand         Asians         137            137                                *IL1RN* (*VNTR*)
  Kammoun-Krichen et al. [@pone.0086077-KammounKrichen1]    2007       Tunisia       Caucasians       131            225        *IL1A* (*-889*), *IL1B (-511)* and *(+3954)* and *IL1RN* (*VNTR*)
  Lacka et al. [@pone.0086077-Lacka1]                       2009       Poland        Caucasians       117            106                           *IL1B (-511)* and *(+3954)*
  Khalilzadeh et al. [@pone.0086077-Khalilzadeh1]           2009        Iran         Caucasians       107            140          *IL1A (-889), IL1B (-511) and (+3954), IL1RN (Mspa-1 11100)*
  Liu et al. [@pone.0086077-Liu1]                           2010        China          Asians         760            735                        *IL1A* (*-889*) and *IL1B (-511)*
  Liu et al. [@pone.0086077-Liu2]                           2010       Taiwan          Asians         484            160                       *IL1B (-31), (-511)* and *(+3954)*

IL-1, interleukin-1; UK, united kingdom; USA, united states of America.

10.1371/journal.pone.0086077.t002

###### Genotype distribution of *IL-1* polymorphisms in patients and controls.

![](pone.0086077.t002){#pone-0086077-t002-2}

  Polymorphism               Patients      Controls                                                                    
  ------------------------ ------------- ------------- ------------- ------- ------------- ------------- ------------- -------
  *IL1B* (*-511*)             CC (%)        TC (%)        TT (%)      Total     CC (%)        TC (%)        TT (%)      Total
  Chen (2005)               29 (30.53)    49 (51.58)    17 (17.89)     95     34 (20.86)    78 (47.85)    51 (31.29)     163
  Kammoun-Krichen (2007)    17 (12.98)    86 (65.65)    28 (21.37)     131    26 (11.56)    165 (73.33)   34 (15.11)     225
  Lacka (2009)              61 (52.14)    40 (34.19)    16 (13.68)     117    67 (63.21)    28 (26.42)    11 (10.38)     106
  Khalilzadeh (2009)        33 (30.84)    60 (56.07)    14 (13.08)     107    36 (25.90)    82 (58.99)    21 (15.11)     139
  Liu (2010)                228 (30.00)   399 (52.50)   133 (17.50)    760    220 (29.93)   351 (47.76)   164 (22.31)    735
  Liu (2010)                154 (32.70)   230 (48.83)   87 (18.47)     471    48 (30.00)    70 (43.75)    42 (26.25)     160
  *IL1B* (*+3954*)            CC (%)        TC (%)        TT (%)      Total     CC (%)        TC (%)        TT (%)      Total
  Reichmann (2004)           3 (5.67)     26 (49.06)    24 (45.28)     53      14 (5.41)    101 (39.00)   144 (55.60)    259
  Chen (2005)               90 (94.74)     5 (5.26)      0 (0.00)      95     155 (95.09)    7 (4.29)      1 (0.61)      163
  Kammoun-Krichen (2007)    26 (19.85)    92 (70.23)     13 (9.92)     131    47 (20.89)    155 (68.89)   23 (10.22)     225
  Lacka (2009)              77 (65.81)    32 (27.35)     8 (6.84)      117    78 (73.58)    24 (22.64)     4 (3.77)      106
  Khalilzadeh (2009)        48 (45.71)    51 (48.57)     6 (5.71)      105    70 (50.00)    58 (41.43)     12 (8.57)     140
  Liu (2010)                458 (97.24)    13 (0.03)     0 (0.00)      471    36 (22.50)    80 (50.00)     44 (27.5)     160
  *IL1RN* (*VNTR*)            LL (%)        2L (%)        22 (%)      Total     LL (%)        2L (%)        22 (%)      Total
  Blakemore (1995)          45 (45.00)    42 (42.00)    13 (13.00)     100    152 (58.24)   92 (35.25)     17 (6.51)     261
  Cuddihy (1996)            83 (58.87)    50 (35.46)     8 (5.67)      141    83 (57.24)    51 (35.17)     11 (7.59)     145
  Mühlberg (1998)           99 (68.75)    33 (22.92)     12 (8.33)     144    104 (59.77)   49 (28.16)    21 (12.07)     174
  Chen (2005)               87 (91.58)     7 (7.37)      1 (1.05)      95     147 (90.18)    15 (9.20)     1 (0.61)      163
  Nakkuntod (2006)          109 (79.56)   25 (18.25)     3 (2.19)      137    106 (77.37)   29 (21.17)     2 (1.46)      137
  Kammoun-Krichen (2007)    92 (70.23)    35 (26.72)     4 (3.05)      131    158 (70.22)   63 (28.00)     4 (1.78)      225

IL-1, interleukin-1.

Association between the *IL1B* (*-511*) polymorphism and GD {#s3b}
-----------------------------------------------------------

Three studies investigating the *IL1B* (*-511*) polymorphism reported on Caucasian populations [@pone.0086077-KammounKrichen1]--[@pone.0086077-Khalilzadeh1], and three on Asians [@pone.0086077-Chen1], [@pone.0086077-Liu1], [@pone.0086077-Liu2]. We found an association between the *IL1B* (*-511*) polymorphism and GD risk in the overall populations in homozygote model (TT vs CC: OR = 0.86, 95% CI: 0.76--0.97, *P~h~* = 0.177, *P~z~* = 0.015) ([Table 3](#pone-0086077-t003){ref-type="table"} and [Fig. 2](#pone-0086077-g002){ref-type="fig"}), but not in dominant and recessive models (TT+TC vs CC: OR = 0.95, 95% CI: 0.81--1.12, *P~h~* = 0.244, *P~z~* = 0.553 and TT vs TC+CC: OR = 0.82, 95% CI: 0.60--1.12, *P~h~* = 0.052, *P~z~* = 0.205, respectively) ([Table 3](#pone-0086077-t003){ref-type="table"} and [Fig. 3](#pone-0086077-g003){ref-type="fig"}). In subgroup analyses stratified by ethnicity, the *IL1B* (*-511*) polymorphism was associated with GD risk in Asians in homozygote and recessive models (TT vs CC: OR = 0.81, 95% CI: 0.70--0.93, *P~h~* = 0.324, *P~z~* = 0.003 and TT vs TC+CC: OR = 0.68, 95% CI: 0.55--0.84, *P~h~* = 0.422, *P~z~*\<0.001, respectively) ([Table 3](#pone-0086077-t003){ref-type="table"}, [Fig. 2](#pone-0086077-g002){ref-type="fig"} and [Fig. 3](#pone-0086077-g003){ref-type="fig"}), but not in dominant model (TT+TC vs CC: OR = 0.92, 95% CI: 0.77--1.11, *P~h~* = 0.265, *P~z~* = 0.389) ([Table 3](#pone-0086077-t003){ref-type="table"}). No association between the *IL1B* (*-511*) polymorphism and GD risk was found in Caucasians in dominant model (TT+TC vs CC: OR = 1.06, 95% CI: 0.76--1.48, *P~h~* = 0.169, *P~z~* = 0.736) ([Table 3](#pone-0086077-t003){ref-type="table"}), recessive model (TT vs TC+CC: OR = 1.26, 95% CI: 0.85--1.86, *P~h~* = 0.438, *P~z~* = 0.244) ([Table 3](#pone-0086077-t003){ref-type="table"} and [Fig. 3](#pone-0086077-g003){ref-type="fig"}) and homozygote model (TT vs CC: OR = 1.07, 95% CI: 0.82--1.41, *P~h~* = 0.405, *P~z~* = 0.600) ([Table 3](#pone-0086077-t003){ref-type="table"} and [Fig. 2](#pone-0086077-g002){ref-type="fig"}).

![Meta-analysis with a fixed effects model for the association between the *IL1B* (*-511*) polymorphism and GD risk in homozygote model.\
Each study is shown by the point estimate of the odds ratio, and a horizontal line denotes the 95% confidence interval. The pooled odds ratio is represented by a diamond. The area of the grey squares reflects the weight of the study in the meta-analysis.](pone.0086077.g002){#pone-0086077-g002}

![Meta-analysis with a random effects model for the association between the *IL1B* (*-511*) polymorphism and GD risk in recessive model.\
Each study is shown by the point estimate of the odds ratio, and a horizontal line denotes the 95% confidence interval. The pooled odds ratio is represented by a diamond. The area of the grey squares reflects the weight of the study in the meta-analysis.](pone.0086077.g003){#pone-0086077-g003}

10.1371/journal.pone.0086077.t003

###### Meta-analysis of polymorphisms in the *IL-1* gene and GD risk.

![](pone.0086077.t003){#pone-0086077-t003-3}

  Polymorphism      No. of studies (Cases/Controls)    Dominant model     Recessive model   Homozygote model                                                                             
  ---------------- --------------------------------- ------------------- ----------------- ------------------ ------------------- --------- ------------- -------------------- --------- -----------
  *IL1B (-511)*                                                                                                                                                                          
  Total                      6 (1681/1528)            0.95 (0.81--1.12)        0.244             0.553         0.82 (0.60--1.12)    0.052       0.205      0.86 (0.76--0.97)     0.177    **0.015**
  Caucasians                  3 (355/470)             1.06 (0.76--1.48)        0.169             0.736         1.26 (0.85--1.86)    0.438       0.244      1.07 (0.82--1.41)     0.405      0.600
  Asians                     3 (1326/1058)            0.92 (0.77--1.11)        0.265             0.389         0.68 (0.55--0.84)    0.422    **\<0.001**   0.81 (0.70--0.93)     0.324    **0.003**
  *IL1B (+3954)*                                                                                                                                                                         
  Total                      6 (972/1053)             0.63 (0.34--1.14)       \<0.001            0.124         0.51 (0.17--1.55)   \<0.001      0.233      0.39 (0.08--1.99)    \<0.001     0.259
  Caucasians                  4 (406/730)             1.02 (0.95--1.09)        0.320             0.640         0.82 (0.56--1.22)    0.449       0.334      1.02 (0.60--1.72)     0.630      0.953
  Asians                      2 (566/323)             0.19 (0.01--5.32)       \<0.001            0.328         0.04 (0.00--8.86)    0.010       0.239      0.02 (0.00--13.04)    0.003      0.240
  *IL1RN (VNTR)*                                                                                                                                                                         
  Total                      6 (748/1105)             0.99 (0.80--1.22)        0.145             0.914         1.12 (0.73--1.68)    0.301       0.636      1.11 (0.73--1.70)     0.149      0.630
  Caucasians                  4 (516/805)             1.02 (0.81--1.29)        0.049             0.875         1.07 (0.69--1.66)    0.119       0.748      1.08 (0.69--1.69)     0.046      0.734
  Asians                      2 (232/300)             0.87 (0.54--1.41)        0.943             0.567         1.57 (0.34--7.15)    0.938       0.561      1.52 (0.33--6.95)     0.931      0.588

CI, confidence interval; GD, Graves\' disease; IL-1, interleukin-1; OR, odds ratio; *P~h~*, *P*-value for heterogeneity; *P~z~*, *P*-value for overall effect.

Significant associations are highlighted in bold.

Association between the *IL1B* (*+3954*) polymorphism and GD {#s3c}
------------------------------------------------------------

For this SNP, four studies were conducted in Caucasians [@pone.0086077-Reichmann1], [@pone.0086077-KammounKrichen1]--[@pone.0086077-Khalilzadeh1], while two studies were performed in Asians [@pone.0086077-Chen1], [@pone.0086077-Liu2]. No association between the *IL1B* (*+3954*) polymorphism and GD risk was observed in the overall populations in dominant model (TT+TC vs CC: OR = 0.63, 95% CI: 0.34--1.14, *P~h~*\<0.001, *P~z~* = 0.124) ([Table 3](#pone-0086077-t003){ref-type="table"}), recessive model (TT vs TC+CC: OR = 0.51, 95% CI: 0.17--1.55, *P~h~*\<0.001, *P~z~* = 0.233) ([Table 3](#pone-0086077-t003){ref-type="table"}) and homozygote model (TT vs CC: OR = 0.39, 95% CI: 0.08--1.99, *P~h~*\<0.001, *P~z~* = 0.259) ([Table 3](#pone-0086077-t003){ref-type="table"}). In subgroup analyses stratified by ethnicity, we found that the *IL1B* (*+3954*) polymorphism was not associated with GD risk in Asians in domiant model (TT+TC vs CC: OR = 0.19, 95% CI: 0.01--5.32, *P~h~*\<0.001, *P~z~* = 0.328) ([Table 3](#pone-0086077-t003){ref-type="table"}), recessive model (TT vs TC+CC: OR = 0.04, 95% CI: 0.00--8.86, *P~h~* = 0.010, *P~z~* = 0.239) ([Table 3](#pone-0086077-t003){ref-type="table"}) and homozygote model (TT vs CC: OR = 0.02, 95% CI: 0.00--13.04, *P~h~* = 0.003, *P~z~* = 0.240)([Table 3](#pone-0086077-t003){ref-type="table"}). No association between the *IL1B* (*+3954*) polymorphism and GD risk was found in Caucasians in dominant model (TT+TC vs CC: OR = 1.02, 95% CI: 0.95--1.09, *P~h~* = 0.320, *P~z~* = 0.640) ([Table 3](#pone-0086077-t003){ref-type="table"}), recessive model (TT vs TC+CC: OR = 0.82, 95% CI: 0.56--1.22, *P~h~* = 0.449, *P~z~* = 0.334) ([Table 3](#pone-0086077-t003){ref-type="table"}) and homozygote model (TT vs CC: OR = 1.02, 95% CI: 0.60--1.72, *P~h~* = 0.630, *P~z~* = 0.953) ([Table 3](#pone-0086077-t003){ref-type="table"}).

Association between the *IL1RN* (*VNTR*) polymorphism and GD {#s3d}
------------------------------------------------------------

Four studies evaluated this polymorphism in Caucasians [@pone.0086077-Blakemore1]--[@pone.0086077-Mhlberg1], [@pone.0086077-KammounKrichen1], while two studies on this polymorphism were performed in Asians [@pone.0086077-Chen1], [@pone.0086077-Nakkuntod1]. We found no association between the *IL1RN (VNTR)* polymorphism and GD risk in the overall populations in dominant model (22+2L vs LL: OR = 0.99, 95% CI: 0.80--1.22, *P~h~* = 0.145, *P~z~* = 0.914) ([Table 3](#pone-0086077-t003){ref-type="table"}), recessive model (22 vs 2L+LL: OR = 1.12, 95% CI: 0.73--1.68, *P~h~* = 0.301, *P~z~* = 0.636) ([Table 3](#pone-0086077-t003){ref-type="table"}) and homozygote model (22 vs LL: OR = 1.11, 95% CI: 0.73--1.70, *P~h~* = 0.149, *P~z~* = 0.630) ([Table 3](#pone-0086077-t003){ref-type="table"}). In subgroup analyses according to ethnicity, we did not find an association between the *IL1RN* (*VNTR*) polymorphism and GD risk in Caucasians and Asians, respectively ([Table 3](#pone-0086077-t003){ref-type="table"}).

Heterogeneity and publication bias {#s3e}
----------------------------------

[Table 3](#pone-0086077-t003){ref-type="table"} showed between-study heterogeneity in details. Begg\'s test was used to evaluate publication bias. No publication bias was present in the analysis assessing the *IL1B* (*-511*), *IL1B* (*+3954*), and *IL1RN* (*VNTR*) polymorphisms. [Table 4](#pone-0086077-t004){ref-type="table"} summarized the results of Begg\'s test in detail.

10.1371/journal.pone.0086077.t004

###### Begg\'s test for evaluating publication bias.

![](pone.0086077.t004){#pone-0086077-t004-4}

  Polymorphism        *P* for Dominant model   *P* for Recessive model   *P* for Homozygote model
  ------------------ ------------------------ ------------------------- --------------------------
  *IL1B* (*-511*)                                                       
  Total                       0.452                     0.707                     0.452
  Caucasians                  1.000                     1.000                     1.000
  Asians                      0.296                     0.296                     0.296
  *IL1B* (*+3954*)                                                      
  Total                       0.707                     1.000                     0.707
  Caucasians                  1.000                     0.308                     1.000
  Asians                      1.000                     1.000                     1.000
  *IL1RN* (*VNTR*)                                                      
  Total                       0.707                     1.000                     0.707
  Caucasians                  1.000                     0.734                     0.734
  Asians                      1.000                     1.000                     1.000

IL-1, interleukin-1.

Discussion {#s4}
==========

Since 1995, many genetic association studies have assessed the relation of the *IL1B* (*-511*) and (*+3954*), and *IL1RN* (*VNTR*) polymorphisms with GD risk; however, the findings remain inconclusive. This may partly be owing to a small sample size of individual studies and distinct genetic background. Meta-analysis is a quantitative statistical analysis that combines the results of previous separate but related studies in order to test the pooled data for statistical significance. It has been increasingly utilized in assessing associations between genetic variants and autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes, and GD [@pone.0086077-Kavvoura1]. In the present study, we undertook a meta-analysis of 11 published case-control studies to investigate the association between the three main *IL-1* gene polymorphisms and GD risk. The main findings were as follows: (1) the *IL1B* (*-511*) polymorphism was associated with GD risk in homozygote model in the overall populations; (2) the *IL1B* (*+3954*) and *IL1RN* (*VNTR*) polymorphisms were not associated with GD risk in any of the genetic models in the overall populations; (3) in Asians, the *IL1B* (*-511*) polymorphism was associated with GD risk in recessive and homozygote models, while the *IL1B* (*+3954*) and *IL1RN* (*VNTR*) polymorphisms were not associated with GD risk; (4) no association between the *IL1B* (*-511*), *IL1B* (*+3954*), and *IL1RN* (*VNTR*) polymorphisms and GD risk was observed in any of the genetic models in Caucasians.

IL-1B is a pluripotential proinflammatory cytokine that primarily produced by B lymphocytes, monocytes and fibroblasts. It is an important mediator for the inflammatory responses and play key roles in the triggering of immune functions, effecting nearly every cell type. IL-1B influenced thyroid cells via a number of underlying mechanisms, including down-regulation of thyroid peroxidase gene expression [@pone.0086077-Ashizawa1], induction of dissociation of the junctional complex [@pone.0086077-Nilsson1], and inhibition of cyclic adenosine monophosphate (cAMP) and thyroglobulin production [@pone.0086077-Rasmussen1]. In the development of GD, infiltration of the thyroid by activated immune cells results in local release of IL-1B. It has been observed that IL-1B induces the production of IL-6, IL-8, intercellular adhesion molecule-1 (ICAM-1), and other inflammatory mediators [@pone.0086077-Dinarello1]--[@pone.0086077-Paik1]. IL-1B also enhances T cell-dependent antibody production by augmenting CD40 ligand and OX40 expression on T cells [@pone.0086077-Nakae1]. IL-1B was shown to promote differentiation of T-helper 17 (Th17) cell, the proportion of which was reported to be higher in intractable GD than that of GD in remission [@pone.0086077-Nanba1]. Therefore, *IL1B* may play a role in the pathogenesis of thyroid autoimmunity. In this meta-analysis, we observed that the *IL1B (-511)* TT genotypes were protective against GD in Asians. This SNP may affect protein expression and function [@pone.0086077-Liu2], [@pone.0086077-AlTahhan1], resulting in down-regulation of inflammatory responses and resistance to develop GD. Several reasons may account for the discrepancy of results between Asians and Caucasians. First, distinct genetic background may play a role. Second, GD is a complex disease which is also related to environmental factors. Genetic susceptibility to GD may be modified by a variety of environmental exposures, leading to differences in genetic associations. Between-study heterogeneity was identified in several pooled analyses. However, when we undertook subgroup analyses according to ethnicity, heterogeneity was greatly reduced, suggesting that ethnicity was the main source of heterogeneity. Other potential factors, such as study design, sample size and genotyping methods, might also contribute to heterogeneity.

Some limitations should be acknowledged when interpreting this meta-analysis. First, our study only included publications written in English. It is possible that some relevant papers written in other languages were missed. Second, all included case-control studies were conducted in Caucasians and Asians. Therefore, the results of this meta-analysis were only applicable to these two ethnic groups. For providing additional evidence of the association between the *IL-1* gene polymorphisms and GD risk, future studies should be performed in other ethnic groups, for example in Latin Americans. Third, although we combined data from all included published case-controls assessing the *IL1B* (*-511*), *IL1B* (*+3954*) and *IL1RN (VNTR)* polymorphisms, the sample size of this meta-analysis was still relatively small, which limited the statistical power to achieve a definitive conclusion. Fourth, haplotype analysis using haplotypes constructed by these SNPs could not be conducted because relevant data provided by included studies were limited. Future association studies are needed to evaluate haplotype associations with GD risk, which will provided more insights for the effects of gene-gene interaction among these SNPs on GD risk.

In summary, our meta-analysis suggested that the *IL1B* (*-511*) polymorphism, but not the *IL1B* (*+3954*) and *IL1RN (VNTR)* polymorphisms was associated with GD risk in Asians, and there was no association between these polymorphisms and GD risk in Caucasians. Future studies should be performed using large sample numbers to establish a more definitive conclusion
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